Great to see more iPSC clinical trials being cleared and taking place in the US.
I don't think the spokesperson (CEO) is incorrect.
From what I can see, IPS HEART's clinical trials attempt to regenerate/regrow muscle - skeletal muscle (DMD / GIVI-MPC) and heart muscle (heart attack / ISX9-CPC). The press release mentions that even the newer (non-IPS) gene therapies "
cannot create any new skeletal muscle".
I would not consider Cynata's FDA cleared IND application or Fate's past, ongoing clinicial trials or FDA cleared IND applications to be disease-modifying.
Cynata has a disease modifying therapy in the form of CYP-004, "
SCUlpTOR - Stem Cells as a symptom- and strUcture-modifying Treatment for medial tibiofemoral OsteoaRthritis", which is however taking place in Australia, not the US.
At this stage, IPS HEART would be the first iPSC disease-modifying clinical trial in the US as far as I can see.
(20min delay)